Next Generation News and Research

RSS

Bristol-Myers Squibb updates its 2009 guidance for GAAP and non-GAAP earnings

Bristol-Myers Squibb Company today updated its 2009 guidance for GAAP and non-GAAP earnings per share from continuing operations.

24 Dec 2009

Planet Green to be acquired by IMAGIN Molecular

IMAGIN Molecular Corporation (OTCBB: IMGM) has agreed in a letter of intent to issue 49% of the post capitalization of IMGM in exchange for 84,000,000 Positron Corporation common shares plus 100% of the equity of the Planet Green Bottle, all IMGM shares to be distributed to shareholders or affiliates of Planet Green.

24 Dec 2009

Scientists use DNA sequence to characterize genome rearrangement in breast cancer samples

The first detailed search of breast cancer genomes to uncover genomic rearrangements is published today. The team characterised the ways in which the human genome is broken and put back together in 24 cases of breast cancer.

23 Dec 2009

Guardian Technologies International meets and presents SM TBDx to Indian healthcare officials

Tuberculosis (TB) continues to be a serious global pandemic health threat with more than 9 million new cases diagnosed annually. TB is a leading cause of mortality in India, killing nearly 1,000 people each day.

23 Dec 2009

Halifax Health Systems receives 2009 InfoWorld 100 Award

Meru Networks, Inc., a pioneer in 802.11n enterprise networking, announced today that its customer Halifax Health Systems, a facilitator of specialized healthcare services in East Central Florida, received an InfoWorld 100 Award for deploying one of the 100 best information technology (IT) projects of 2009. Halifax’s wireless LAN (WLAN) infrastructure employs Meru Networks high-performance 802.11n technology as the foundation for wireless connectivity in their new 500,000 square foot state-of-the-art medical facility in Daytona Beach, Florida.

22 Dec 2009

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.

22 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel’s Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel’s Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).

18 Dec 2009

Joe Chimera, the 25th person to receive MEP Certification from PHII

The Population Health Impact Institute (PHII) is pleased to announce that Joe Chimera, Ph.D., is the 25th person to receive the Methods Evaluation Process (MEP) Certification.

18 Dec 2009

NiTi Surgical Solutions' ColonRing used for the first time in a colorectal surgery in China

NiTi™ Surgical Solutions, an innovative surgical device company, today announced that its ColonRing™, the first major advance in closure for gastrointestinal surgery in more than 30 years, has been used for the first time in a colorectal surgery in China. The ColonRing anastomosis device was launched in the United States in May 2008 and has been successfully applied in thousands of patients.

18 Dec 2009

Interactive health assessment system from RedBrick Health

RedBrick Health, the Health EarningsSM company, today announced the launch of its own next-generation, highly interactive health assessment. Integral to RedBrick’s Health Earnings System, the company’s new health assessment is compact, conversational and graphical, all significant departures from conventional health assessments.

18 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Aided by next-generation DNA sequencing technology, an international team of researchers has gained insights into how more than 60 carcinogens associated with cigarette smoke bind to and chemically modify human DNA, ultimately leading to cancer-causing genetic mutations.

17 Dec 2009

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that Cancer Research UK’s Drug Development Office – the drug development arm of the world’s largest independent organization dedicated to cancer research – is standardizing on Phase Forward’s InForm™ Global Trial Management solution to support its diverse portfolio of early-stage clinical trials.

17 Dec 2009

Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone payment from Pfizer Inc. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of a novel monoclonal antibody therapeutic that was optimized using Xencor technologies under a March 2009 technology license agreement.

16 Dec 2009

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

16 Dec 2009

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

Safe Life increases production of its A400 Series respirators

Safe Life Corp., an innovative antimicrobial company dedicated to developing novel technologies that prevent the spread of infection and disease, announced today that it is ramping production of its comfortable, breathable, A400 Series respirator to help healthcare providers and government agencies address the global shortage of N95 respirators during the H1N1 pandemic.

15 Dec 2009

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it has signed an exclusive license and commercialization agreement with Mayo Clinic to further develop and commercialize a suite of technologies invented by a team of Mayo physicians and scientists, headed by Michael O'Connor, PhD.

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

Next Generation News and Research

Bristol-Myers Squibb updates its 2009 guidance for GAAP and non-GAAP earnings

Planet Green to be acquired by IMAGIN Molecular

Scientists use DNA sequence to characterize genome rearrangement in breast cancer samples

Guardian Technologies International meets and presents SM TBDx to Indian healthcare officials

Halifax Health Systems receives 2009 InfoWorld 100 Award

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Joe Chimera, the 25th person to receive MEP Certification from PHII

NiTi Surgical Solutions' ColonRing used for the first time in a colorectal surgery in China

Interactive health assessment system from RedBrick Health

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

Safe Life increases production of its A400 Series respirators

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Molecular Partners closes its CHF 46 million Series B equity investment round

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News